Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 284, Issue 2 53-2, 2003, Pages

  Trillou, Christine Ravinet ^a   Arnone, Michèle ^a   Delgorge, Claire ^a   Gonalons, Nadine ^a   Keane, Peter ^a   Maffrand, Jean Pierre ^a   Soubrié, Philippe ^a  

^a SANOFI   (France)

Author keywords

Body weight; CB1 receptor knockout mice; Endocannabinoid; Food intake; Insulin resistance; Metabolic rate

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; FATTY ACID; INSULIN; LEPTIN; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; FEEDING BEHAVIOR; FOOD INTAKE; INSULIN RESISTANCE; KNOCKOUT MOUSE; MALE; METABOLIC RATE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; WEIGHT REDUCTION;

EID: 0037304290     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00545.2002     Document Type: Article

References (62)

1. Abel EL. Cannabis: effects on hunger and thirst. Behav Biol 15: 255-281, 1975.
2. Ahrén B, Simonsson E, Scheurink AJW, Mulder H, Myrsén U, and Sundler F. Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice. Metabolism 46: 97-106, 1997.
3. Alonso R, Voutsinos B, Fournier M, Labie C, Steinberg R, Souilhac J, Le Fur G, and Soubrié P. Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function. Neuroscience 91: 607-620, 1999.
4. American Physiological Society. Guiding principles for research involving animals and human beings. Am J Physiol Regul Integr Comp Physiol 283: R281-R283, 2002.
5. Andersson LB. Genes and obesity. Ann Med 28: 5-7, 1996.
6. Arnold JC, Topple AN, Mallet PE, Hunt GE, and McGregor IS. The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain. Brain Res 921: 240-255, 2001.
7. Arnone M, Jung M, Keane PE, Maffrand JP, and Soubrié P. The CB1 cannabinoid receptor antagonist SR141716 reduces sucrose intake and fat diet preference in lean and obese rats (Abstract). Int J Obes 23, Suppl 5: S63, 1999.
8. Arnone M, Maruani J, Chaperon F, Thiébot MH, Poncelet M, Soubrié P, and Le Fur G. Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 132: 104-106, 1997.
9. Breivogel CS, Sim LJ, and Childers SR. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J Pharmacol Exp Ther 282: 1632-1642, 1997.
10. Burcelin R, Crivelli V, Dacosta A, Roy-Tirelli A, and Thorens B. Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet. Am J Physiol Endocrinol Metab 282: E834-E842, 2002.
11. Chen Y and Heiman ML. Chronic leptin administration promotes lipid utilization until fat mass is greatly reduced and preserves lean mass of normal female rats. Regul Pept 92: 113-119, 2000.
12. Colombo G, Agabio R, and Diaz G. Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci 63: 113-117, 1998.
13. Commins SP, Marsh DJ, Thomas SA, Watson PM, Padgett MA, Palmiter R, and Gettys TW. Norepinephrine is required for leptin effects on gene expression in brown and white adipose tissue. Endocrinology 140: 4772-4778, 1999.
14. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, and Caro JF. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334: 292-295, 1996.
15. Di Marzo V, Goparaju SK, Wang L, Liu J, Bátkai S, Járai Z, Fezza F, Miuras GI, Palmiter RD, Sugiura T, and Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410: 822-825, 2001.
16. Dickinson K, North TJ, Telford G, Smith S, Brammer R, Jones RB, and Heal DJ. Determination of body composition in conscious adult female Wistar utilising total body electrical conductivity. Physiol Behav 74: 425-433, 2001.
17. Elmquist JK, Elias CF, and Saper CB. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 22: 221-232, 1999.
18. Elmquist JK, Maratos-Flier E, Saper CB, and Flier JS. Unraveling the central nervous system pathways underlying responses to leptin. Nat Neurosci 1: 445-450, 1998.
19. Forbes S, Bui S, Robinson BR, Hochgeschwender U, and Brennan MB. Integrated control of appetite and fat metabolism by the leptin-proopiomelanocortin pathway. Proc Natl Acad Sci USA 98: 4233-4237, 2001.
20. Friedman JM and Halaas JL. Leptin and the regulation of body weight in mammals. Nature 395: 763-770, 1998.
21. 1 receptor mRNA in the pituitary gland. Neuroendocrinology 70: 137-145, 1999.
22. Han DH, Hansen PA, Host HH, and Holloszy JO. Insulin resistance of muscle glucose transport in rats fed a high-fat diet. Diabetes 46: 1761-1767, 1997.
23. Kahn BB and Flier JS. Obesity and insulin resistance. J Clin Invest 106: 473-481, 2000.
24. Kim JY, Nolte LA, Hansen PA, Han DH, Ferguson K, Thompson PA, and Holloszy JO. High-fat diet-induced muscle insulin resistance: relationship to visceral fat mass. Am J Physiol Regul Integr Comp Physiol 279: R2057-R2065, 2000.
25. Kirkham TC and Williams CM. Endogenous cannabinoids and appetite. Nutr Res Rev 14: 65-86, 2001.
26. Kirkham TC, Williams CM, Fezza F, and Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136: 550-557, 2002.
27. 9-THC stimulates food intake in Lewis rats. Effects on chow, high-fat and sweet high-fat diets. Pharmacol Biochem Behav 68: 539-543, 2001.
28. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Böhme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, and Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283: 401-404, 1999.
29. Lemonnier D, Suquet JP, Aubert R, De Gasquet P, and Pequignot E. Metabolism of the mouse made obese by a high-fat diet. Diabetes Metab 1: 77-85, 1975.
30. Levin BE and Dunn-Meynell A. A Reduced central leptin sensitivity in rats with diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 283: R941-R948, 2002.
31. Li B, Nolte LA, Ju JS, Han DH, Coleman T, Holloszy JO, and Semenkovich CF. Skeletal muscle respiratory uncoupling prevents diet-induced obesity and insulin resistance in mice. Nat Med 6: 1115-1120, 2000.
32. Lin L, Martin R, Schaffhauser AO, and York DA. Acute changes in the response to peripheral leptin with alteration in the diet composition. Am J Physiol Regul Integr Comp Physiol 280: R504-R509, 2001.
33. Lin S, Thomas TC, Storlien LH, and Huang XF. Development of high fat diet-induced obesity and leptin resistance in C57B1/6J mice. Int J Obes Relat Metab Disord 24: 639-646, 2000.
34. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern PA, and Friedman JM. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1: 1155-1161, 1995.
35. McGregor IS, Arnold JC, Weber MF, Topple AN, and Hunt GE. A comparison of delta 9-THC and anandamide induced c-fos expression in the rat forebrain. Brain Res 802: 19-26, 1998.
36. Moldrich G and Wenger T. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides 21: 1735-1742, 2000.
37. Portillo MP, Cantoral R, and Macarulla MT. Effects of dietary fat content on adiposity during energy restriction in genetically obese rats. Reprod Nutr Dev 39: 189-199, 1999.
38. Rebuffé-Scrive M, Surwit R, Feinglos M, Kuhn C, and Rodin J. Regional fat distribution and metabolism in a new mouse model (C57BL/6J) of non-insulin-dependent diabetes mellitus. Metabolism 42: 1405-1409, 1993.
39. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, Ferrara P, Soubrié P, Brelière JC, and Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350: 240-244, 1994.
40. Robbe D, Kopf M, Remaury A, Bockaert J, and Manzoni OJ. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci USA 99: 8384-8388, 2002.
41. Ross R, Dagnone D, Jones PJH, Smith H, Paddags A, Hudson R, and Janssen I. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. Ann Intern Med 133: 92-103, 2000.
42. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, and Baskin DG. Central nervous system control of food intake. Nature 404: 661-671, 2000.
43. Simiand J, Keane M, Keane PE, and Soubrié P. SR141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 9: 179-181, 1998.
44. Sindelka G, Skrha J, Prazny M, and Haas T. Association of obesity, diabetes, serum lipids and blood pressure regulates insulin action. Physiol Res 51: 85-91, 2002.
45. Solin MS, Ball MJ, Robertson I, De Silva A, Pasco Kotowicz MA JA, Nicholson GC, and Collier GR. Relationship of serum leptin to total and truncal body fat. Clin Sci (Colch) 93: 581-584, 1997.
46. Steinberg GR, Bonen A, and Dyck DJ. Fatty acid oxidation and triacylglycerol hydrolysis are enhanced after chronic leptin treatment in rats. Am J Physiol Endocrinol Metab 282: E593-E600, 2002.
47. Takahashi M, Ikemoto S, and Ezaki O. Effect of the fat/carbohydrate ratio in the diet on obesity and oral glucose tolerance in C57BL/6J mice. J Nutr Sci Vitaminol (Tokyo) 45: 583-593, 1999.
48. Triscari J, Nauss-Karol C, Levin BE, and Sullivan AC. Changes in lipid metabolism in diet-induced obesity. Metabolism 34: 580-587, 1985.
49. Trocki O, Baer DJ, and Castonguay TW. An evaluation of the use of total body electrical conductivity for the estimation of body composition in adult rats: effect of dietary obesity and adrenalectomy. Physiol Behav 57: 765-772, 1995.
50. Tzavara ET, Perry KW, Rodriguez DE, Bymaster FP, and Nomikos GG. The cannabinoid CB1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus. Eur J Pharmacol 426: R3-R4, 2001.
51. Van Heek M, Compton DS, France CF, Tedesco RP, Fawzi AB, Graziano MP, Sybertz EJ, Strader CD, and Davis HR Jr. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 99: 385-390, 1997.
52. Varvel SA and Lichtman AH. Evaluation of CB1 receptor knockout mice in the Morris water maze. J Pharmacol Exp Ther 301: 915-924, 2002.
53. Wadden TA. Treatment of obesity by moderate and severe caloric restriction. Results of clinical research trials. Ann Intern Med 119: 688-693, 1993.
54. Wenger T, Gerendai I, Fezza F, González S, Bisogno T, Fernandez-Ruiz J, and Di Marzo V. The hypothalamic levels of the endocannabinoid, anandamide, peak immediately before the onset of puberty in female rats. Life Sci 70: 1407-1414, 2002.
55. Widdowson PS, Upton R, Buckingham R, Arch J, and Williams G. Inhibition of food response to intracerebroventricular injection of leptin is attenuated in rats with diet-induced obesity. Diabetes 46: 1782-1785, 1997.
56. Williams CM and Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 143: 315-317, 1999.
57. 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol Biochem Behav 71: 341-348, 2002.
58. 9-THC and anandamide. Physiol Behav 76: 241-250, 2002.
59. 9-THC. Physiol Behav 65: 343-346, 1998.
60. Williams TD, Chambers JB, May OL, Henderson RP, Rashotte ME, and Overton JM. Concurrent reductions in blood pressure and metabolic rate during fasting in the unrestrained SHR. Am J Physiol Regul Integr Comp Physiol 278: R255-R262, 2000.
61. Zaho J, Cannon B, and Nedergaard J. Alpha1-adrenergic stimulation potentiates the thermogenic action of beta3-adrenoreceptor-generated cAMP in brown fat cells. J Biol Chem 272: 32847-32856, 1997.
62. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, and Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96: 5780-5785, 1999.